Page 10 - Adamm Hill News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oncimmune climbs on contract news but Ormonde Mining slumps as deal collapses

Oncimmune climbs on contract news but Ormonde Mining slumps as deal collapses
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCity ofHot creek valleyAbu sennanPatrick desouzaBrian larkinGraeme purdyBill smithNueva andromedaRoger bullenStacey solomonAdamm hillOncimmune serotagJonathan henryProspex energy

Oncimmune losses narrow as sales rise | 15 February 2021

15 February 2021 | 07:54am StockMarketWire.com - Immunodiagnostics group Oncimmune posted a narrower first-half loss on the back of higher revenue and lower R&D spending. Pre-tax losses for the six months through November amounted to £2.8 million, compared to losses of £5.5 million year-on-year. Revenue rose to £1.8 million, up from £0.3 million. Oncimmune said it saw a marked increase in commercial activity as large pharmaceutical and biotech companies utilised its biomarker discovery platform technology tools. Seven such contracts had been signed in the period, including with Roche Pharmaceuticals and Genentech, with work on those recently completed or very advanced. In addition, first commercial contracts had been signed to supply a lung cancer diagnostic blood test to the National Health Service, with patient samples already analysed.

Adamm hillRoche pharmaceuticalsNational health serviceOncimmune holdings plcLon oncOnc lரோச் மருந்துகள்தேசிய ஆரோக்கியம் சேவைலோன் ஆஂக்ஆஂக் ல்

Investegate | Company News | Corporate, London Stock Exchange, Regulatory News Headlines Oncimmune losses narrow as sales rise

Investegate, Oncimmune losses narrow as sales rise by BFN News From InvestEgate

Adamm hillRoche pharmaceuticalsNational health serviceCompany newsCorporate newsStock newsStock exchange newsLse newsRegulatory newsCompany press releasesInvestegate newsBfn newsரோச் மருந்துகள்தேசிய ஆரோக்கியம் சேவைநிறுவனம் செய்திபெருநிறுவன செய்தி

Oncimmune Holdings Collaboration demonstrates the utility of autoantibodies in Methotrexate and Tocilizumab treatment selection

Oncimmune Holdings Collaboration demonstrates the utility of autoantibodies in Methotrexate and Tocilizumab treatment selection 7:15 am Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the publication by PLOS ONE of a study, supported by the Oncimmune’s ImmunoINSIGHTS team, which analysed autoantibodies in patients with newly diagnosed Rheumatoid Arthritis (RA) who were treated with either Tocilizumab or Methotrexate monotherapy. This work significantly expanded the biomarkers commonly measured in RA patients to develop a detailed picture of the immune response to the disease and its treatment. The aim of the study was to develop a set or panel of predictive biomarkers to identify an early response in RA patients to Methotrexate or Tocilizumab, Roche’s interleukin-6 (IL-6) receptor inhibitor.

Adamm hillOncimmune immunoOncimmune holdingsRheumatoid arthritisRheumatoid factorமுடக்கு கீல்வாதம்முடக்கு காரணி